The wait that Duchenne families were told might stretch has now been given a date. The Food and Drug Administration has pushed back its decision on the cell therapy Deramiocel from August 22 to November 22, 2026, using a specific regulatory mechanism that carries consequences.
Capricor Therapeutics announced the extension of its target action date, saying the agency classified its recent submission as a major amendment, a designation that by rule adds three months to the review clock. The Center for Biologics Evaluation and Research accepted the amendment for review, citing the significant unmet medical need in Duchenne muscular dystrophy.
The amendment includes 24-month open-label extension data from the Phase 3 HOPE-3 study, along with additional robustness analyses. The company is now asking the agency to assess the therapy based on upper limb function, the trial's primary endpoint, rather than on the heart muscle disease targeted in the original application.
For families, that combination is the practical news. A defined 90-day window replaces an open-ended question, and the thing the FDA is being asked to approve has taken a different shape.
The Question Families Now Face Is Different
Three months is not an abstraction in a progressive disease. Duchenne affects roughly 15,000 people in the United States, primarily boys, and the function that is lost is not recovered. A family whose son is losing the ability to feed himself or operate a wheelchair control is measuring the delay against that trajectory.
Linda Marbán, Ph.D., Capricor's chief executive, emphasized that specific loss. In a disease where function cannot be recovered once lost, she said, "preservation of upper limb function has the potential to translate into meaningful differences" in patients' independence and daily lives.
The shift in target also changes the practical question a parent should be asking. The earlier application concerned cardiomyopathy, which is the leading cause of death in Duchenne and for which no therapy is approved. The refined request concerns arm and hand function. Even a favorable outcome in November would answer a different question than the one families have been following through the summer, and it would not result in an approved cardiac treatment.
Nothing about care changes in the meantime. Deramiocel remains investigational and is not available by prescription. Cardiology and pulmonology follow-up should stay on schedule rather than being deferred in anticipation of a regulatory outcome, and medication questions belong with the treating team.
The Path from a July Vote to a November Date
The sequence explains why this step counts as news rather than repetition.
On July 29 the FDA's Cellular, Tissue and Gene Therapies Advisory Committee voted 9 to 3 against the cardiomyopathy evidence, concluding that available data did not support the effectiveness of deramiocel for that use. The vote was non-binding and covered a narrower indication than the company had proposed. Panelists said results appeared sensitive to how missing data were handled and were skeptical that a cardiac imaging measure served as a validated stand-in for clinical benefit. In a separate discussion of upper limb function, the committee's feedback was more supportive, according to the company.
MedicalDaily previously reported that the company would amend its filing to seek an upper-limb indication and that the August 22 date was likely to move. At that point, two questions were open: whether the amendment would actually be filed, and whether the agency would classify it as major, since that classification is what attaches a defined new timeline.
Both are now answered. The amendment was filed; the agency called it "major," and November 22 is the new target action date. That is the material change.
Confirmed, Contested, and Still Unresolved
Readers should keep three categories separate.
Confirmed: the new date, the major amendment classification, the contents of the amendment, and the agency's acceptance of it for review.
Contested: whether HOPE-3 demonstrates effectiveness. Capricor states that the trial met its primary endpoint, showing a statistically significant benefit in upper-limb function, and that the full dataset was published in The Lancet in July after peer review. FDA reviewers and most advisory committee members were not persuaded by the broader evidence package, and the dispute centers on which version of the statistical analysis plan governs the interpretation. Both positions are on the record, and neither has been resolved by the extension.
Unresolved: whether the agency approves anything in November. A target action date is a deadline for a decision, not a signal of what the decision will be. It is unusual, though not impossible, for the FDA to approve a product after a negative advisory vote. A July bioresearch monitoring inspection also produced a Form 483 citing one observation, and the company says it has responded and is awaiting feedback.
Preparation That Is Worth Doing Before November
No action improves the odds of approval, and families should be wary of anyone suggesting otherwise.
What is useful is preparation. Families can ask their neuromuscular team how upper limb function is measured in their child's care and whether those assessments are documented, because functional measurements recorded over time are what payers and prescribers use when a therapy becomes available. Enrolling in a Duchenne patient registry is free and is how researchers and sponsors identify candidates when trials or access programs open.
Cost planning is also worth starting early. Cell therapies for rare diseases carry high list prices and require prior authorization, and no price for Deramiocel has been announced. Advocacy organizations, including Parent Project Muscular Dystrophy and CureDuchenne, track program news and have posted community updates after previous regulatory milestones.
The next scheduled milestone is the target action date of November 22. Between now and then, the agency may or may not communicate publicly. MedicalDaily will report any FDA action, any further change to the review timeline, and the outcome when it is issued.
Key Questions Answered
What changed? The FDA moved its target action date for deramiocel from August 22 to November 22 and classified Capricor's new submission as a major amendment, which automatically adds 3 months to the review period.
What is in the new submission? Twenty-four months of open-label extension data from the Phase 3 HOPE-3 study, plus additional robustness analyses, were submitted in support of a refined indication focused on upper limb function.
Is the company still seeking approval for the heart disease? The refined request centers on upper-limb function, the trial's primary endpoint, rather than on the cardiomyopathy indication that the advisory committee voted on.
Does the extension mean approval is more likely? No. A target action date is a deadline for a decision, not an indication of the outcome. The agency has not signaled how it will rule.
Is Deramiocel available now? No. It is investigational and cannot be prescribed. No therapy is currently approved specifically for Duchenne cardiomyopathy.
Should families change anything about current care? No. Keep cardiology and pulmonology appointments on schedule and discuss any treatment questions with the neuromuscular team rather than acting on regulatory news.
When is the next milestone? November 22, 2026, the new target action date.
